← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › VIRAL VACCINES › Encephalitis vaccines
encephalitis, tick borne, inactivated, whole virus
J07BA01
Forms & Strengths
- Suspension for intramuscular injection, 0.25 mL (pediatric formulation)
- Suspension for intramuscular injection, 0.5 mL (adult formulation)
Adult Dosing
- Primary immunization: 0.5 mL IM on days 0, 14-21, and 9-12 months after the first dose
- Rapid schedule: 0.5 mL IM on days 0, 7, and 21 (optional alternative)
- Booster doses: First booster 3 years after primary series, subsequent boosters every 3-5 years based on exposure risk
Pediatric Dosing
- Ages 1-15 years (varies by regional product labeling): 0.25 mL IM on days 0, 14-21, and 9-12 months after the first dose
- Booster doses: First booster 3 years after primary series, subsequent boosters every 3-5 years
Indications
- Active immunization against tick-borne encephalitis (TBE) in individuals living in or traveling to endemic areas
Mechanism of Action
- Inactivated whole-virus vaccine stimulates the production of neutralizing antibodies against the tick-borne encephalitis virus, conferring active immunity
Contraindications
- Severe hypersensitivity to the active substance, any excipients, or residual components from the manufacturing process (e.g., formaldehyde, protamine sulfate, traces of chicken egg protein)
- Anaphylactic reaction to a previous dose of tick-borne encephalitis vaccine
- Acute severe febrile illness (defer vaccination until resolution)
Adverse Reactions
- Local injection site reactions: pain, tenderness, erythema, swelling
- Systemic reactions: fatigue, headache, myalgia, arthralgia, fever, nausea
- Rare: hypersensitivity reactions, anaphylaxis, neurological disorders (e.g., aseptic meningitis, encephalomyelitis)
Drug Interactions
- Immunosuppressive therapies may reduce the immune response to the vaccine
- Can be administered concomitantly with most inactivated travel vaccines using separate injection sites
- Postpone administration of other live vaccines if possible, though generally minimal interaction with inactivated viral vaccines
Curated Content: Needs Vetting Before Put to Clinical Use